Ruipu Biotech released its 2026 interim report. In the first half, it achieved operating revenue of 1.72 billion yuan, up 0.8% year on year, while net profit attributable to the parent company was 204 million yuan, down 20.4% year on year. The company said that after excluding the impact of the VAT rate change on biological products, and on a comparable basis with the same period last year, operating revenue grew 4.51% year on year, and non-GAAP net profit attributable to the parent company rose more than 27% year on year. Since January 1 this year, biological products have no longer been eligible for the 3% simplified VAT levy method and are uniformly taxed at 13%, and this policy adjustment affected current-period net profit by about 54.49 million yuan. The livestock and poultry animal health business achieved operating revenue of 1.191 billion yuan, a decrease of 74.01 million yuan year on year; after excluding the VAT policy impact, revenue was basically flat year on year. The pet business achieved revenue of 479 million yuan, up 15.43% year on year, and international business revenue was 93.32 million yuan, up 45.19% year on year.
Tianjin Ringpu Bio TechNet profit fell 20.4% due to VAT policy change, though adjusted profit rose 27%.
